Country | Prevalence and criteria used (%) | Reference | |||
Sample size | Manning | Rome I | Rome II | ||
UK | 301 | 13.6 | Thomson & Heaton, 198015 | ||
UK | 1620 | 22 | Jones & Lydeard, 199216 | ||
UK | 1896 | 9.5 | Heaton et al, 199217 | ||
UK | 3179 | 16.7 | Kennedy & Jones, 200018 | ||
UK | 3111 (PC*) | 2.5 | Thomson et al, 200019 | ||
UK | 4807 | 10.5 | Wilson et al, 200520 | ||
USA | 789 | 17.1 | Drossman et al, 198221 | ||
USA | 566 | 15.0 | Sandler et al, 198422 | ||
USA | 835 | 8.7 to 17.0 | Talley et al, 199123 | ||
USA | 325 | 4.9 to 10.9 | Talley et al, 199224 | ||
USA | 5430 | 11.6 | Drossman et al, 199325 | ||
USA | 3022 | 20.0 | Talley et al, 199526 | ||
USA | 643 | 8.6 to 20.4 | Saito et al, 200027 | ||
USA | 643 | 6.8 | 4.7 | Saito et al, 200328 | |
USA | 5009 | 14.1 | Hungin et al, 200529 | ||
Canada | 1149 | 13.5 | 13.1 | Thompson et al, 200230 | |
Canada | 437 | 2.5 | Li et al, 200331 | ||
Australia | 2910 | 16.7 | Boyce et al, 200032 | ||
New Zealand | 980 | 18.8 | 3.3 | Barbezat et al, 200233 | |
Netherlands | 438 | 5.8 | Boekema et al, 200134 | ||
Spain | 2000 | 4.4 to 13.6 | Mearin et al, 200135 | ||
Italy | 533 | 8.5 | Gaburri et al, 198936 | ||
France | 20,000 | 4.7 | Coffin et al, 200437 | ||
Denmark | 4581 | 6.6 | Agreus et al, 199538 | ||
Finland | 3631 | 9.7 to 16.2 | 5.5 | 5.1 | Hillila & Farkkila, 200439 |
Sweden | 1290 | 14.0 | Kay et al, 199440 | ||
Iran | 4762 | 5.8 | Hoseini-Asl & Amra, 200341 | ||
Turkey | 998 | 19.1 | Karaman et al, 200342 | ||
Turkey | 1766 | 6.3 | Celebi et al, 200443 | ||
Bangladesh | 2426 | 8.5 | Masud et al, 200144 | ||
Hong Kong | 1000 | 6.6 | Kwan et al, 200246 | ||
Hong Kong | 1298 | 17.4 | 3.7 | Lau et al, 200247 | |
Japan | 231 | 25.0 | Schlemper et al, 199348 | ||
Singapore | 696 | 2.3 | Ho et al, 199849 | ||
South China | 4178 | 13.0 | Xiong et al, 200450 | ||
Singapore | 2276 | 11.0 | 10.4 | 8.6 | Gwee et al, 200451 |
Malaysia | 949 | 15.7 | Rajendra & Alahuddin, 200452 |
*PC, primary care patients.